FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
This article was originally published in The Tan Sheet
Executive Summary
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders